Twenty-two patients with hairy cell leukemia were treated with biosynthetic (recombinant) alpha-2-interferon in an open-label, single- arm efficacy study. Patients received 2 X 10(6) U/m2 recombinant alpha- 2-interferon three times weekly. Therapy was well tolerated subjectively with minimal short-term hematologic toxicity. Two patients had bacterial infections during the period of study, and one patient experienced a short-lived readily reversible rejection of a corneal transplant. Statistical comparison of the mean hematologic indices at study entry and after three to six months of therapy with recombinant alpha-2-interferon indicates a significant improvement in hemoglobin, granulocyte, and platelet counts. Bone marrow biopsies in six of 14 patients after six months of therapy showed a greater than 50% decrease in the infiltration of leukemia cells. We conclude that recombinant alpha-2-interferon is highly effective therapy for hairy cell leukemia.
ARTICLES| April 1, 1985
Recombinant alpha-2-interferon for hairy cell leukemia
Blood (1985) 65 (4): 1017-1020.
- Share Icon Share
- Tools Icon Tools
- Search Site
- PDF LinkPDF
AD Jacobs, RE Champlin, DW Golde; Recombinant alpha-2-interferon for hairy cell leukemia. Blood 1985; 65 (4): 1017–1020. doi: https://doi.org/10.1182/blood.V65.4.1017.bloodjournal6541017
Download citation file: